Key facts
- This page summarizes Thomas Folinsbee's Form 4 filing for Summit Healthcare Acquisition Corp..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 21 Mar 2023, 06:21.
Thomas Folinsbee - 16 Mar 2023 Form 4 Insider Report for Summit Healthcare Acquisition Corp.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 16 Mar 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Mar 2023, 06:21:44 UTC
- Prior SEC filing
- 08 Jun 2021
- Next SEC filing
- 23 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Bo Tan, as attorney-in-fact for Folinsbee Thomas
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Thomas Folinsbee filed Form 4 for Summit Healthcare Acquisition Corp. on 21 Mar 2023.
Change
- Previous filing in this sequence was filed on 08 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SMIHU
transaction
Derivative
Class B Ordinary Shares
Disposed to Issuer
- Transaction value
- Shares
- -25,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Mar 2023
- Ownership
- Direct
- Underlying class
- Class A Ordinary Shares
- Underlying amount
- 25,000
- Exercise price
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Thomas Folinsbee is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
As described in the prospectus for the initial public offering (File No. 333-255722) of Summit Healthcare Acquisition Corp. ("SMIH") under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, automatically converted into Class A ordinary shares, par value $0.0001 per share, of SMIH at the time of the SMIH's initial business combination, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights.
Footnote F2
On March 16, 2023, pursuant to a Business Combination Agreement dated as of September 29, 2022 (the "Business Combination Agreement"), by and among SMIH, YishengBio Co., Ltd ("YS Biopharma"), Oceanview Bioscience Acquisition Co., Ltd., a direct wholly owned subsidiary of YS Biopharma ("Merger Sub I") and Hudson Biomedical Group Co., Ltd., a direct wholly owned subsidiary of YS Biopharma ("Merger Sub II"), (i) Merger Sub I merged with and into SMIH (the "First Merger"), with SMIH surviving the First Merger as the surviving entity (the "Surviving Entity") and remaining as a wholly-owned subsidiary of YS Biopharma and (ii) the Surviving Entity merged with and into Merger Sub II (the "Second Merger"), with Merger Sub II surviving the Second Merger as the surviving company (the "Surviving Company") and remaining as a wholly-owned subsidiary of YS Biopharma.
Footnote F3
(Continued from Footnote 2) Immediately before the effective time of the First Merger, an aggregate of 1,446,525 Class B ordinary shares held by Summit Healthcare Acquisition Sponsor LLC, a Cayman Islands limited liability company (the "Sponsor") was surrendered for nil consideration, and after such surrender, each Class B ordinary share ceased to be outstanding and automatically converted into the right to receive one ordinary share of YS Biopharma.